Director/PDMR Shareholding

hVIVO

24/04/2026 18:14

RNS Number : 9139B

hVIVO PLC

24 April 2026

 

 

hVIVO plc

("hVIVO", the "Company" or the "Group")

 

Director/PDMR Dealings

 

London, UK - 24 April 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, has been notified that Brendan Buckley, Non-Executive Director, has sold 2,017,000 ordinary shares of £0.001 each in the Company ("Ordinary Shares") at a price of 8.65p per Ordinary Share.

 

Following this transaction, Brendan Buckley, who has informed the Company of his intention not to stand for re-election at the upcoming AGM, now holds 2,000,270 Ordinary Shares in the Company.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain. 

 

For further information please contact:

 

hVIVO plc
+44 (0)20 7756 1300
Yamin'Mo' Khan, Chief Executive Officer
Stephen Pinkerton, Chief Financial Officer
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)
+44 (0)20 7220 0500
Geoff Nash, Callum Davidson
 Trisyia Jamaludin, Harriet Ward
Nigel Birks - Life Science Specialist Sales
Louise Talbot - Sales
Peel Hunt LLP (Joint Broker)
+44 (0)20 7418 8900
James Steel, Dr Christopher Golden
Davy (Joint Broker)
+353 (0) 1 679 6363
Anthony Farrell, Niall Gilchrist
ICR Healthcare (Financial PR & IR)
Mary-Jane Elliott / Stephanie Cuthbert / Phillip Marriage / Louis Ashe-Jepson
hVIVO@icrhealthcare.com


 

Notes to Editors

 

hVIVO plc (AIM: HVO) is a purpose-built, full-service international clinical development partner and the global leader in human challenge trials, serving seven of the world's ten largest biopharma companies.

 

The Company has an end-to-end platform designed to bring important medicines to patients faster: spanning preclinical strategy, first‑in‑human studies, Phase II patient trials and specialist laboratory services, delivered through a large participant database, wholly owned sites and laboratories across the UK and Germany.

 

With a combined Group heritage of more than 100 years, hVIVO delivers an accelerated pathway to clinical proof-of-concept through four integrated service lines: Consulting, Clinical Trials, Human Challenge Trials, and Laboratories.

 

·    Consulting provides expert-led preclinical and clinical strategy, encompassing non-clinical, clinical, CMC, pharmacokinetics, data management, biostatistics, and regulatory support to guide trial design, execution, and interpretation.

·    Clinical Trials offers Phase I/II CRO services, Phase II/III site services across the UK and Germany, and specialist recruitment through FluCamp, Europe's largest recruitment database.

·    Human Challenge Trials leverages hVIVO's state-of-the-art quarantine facility in London - the largest of its kind worldwide - to deliver fast, controlled, high-quality efficacy data through guaranteed viral exposure.

·    Laboratories provides cutting-edge virology and immunology laboratory services, including biobanking and sample storage, supporting both challenge trials and standalone client studies.

 

 

1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name of PDMR
Brendan Buckley
2
Reason for notification
a.
Position/Status
Non-Executive Director
b.
Initial notification/
Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
hVIVO plc
b.
LEI
213800VT5KBM7JLIV118
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument
Identification Code
Ordinary shares of £0.001 each
ISIN GB00B9275X97
b.
Nature of the transaction
Sale of Ordinary Shares
c.
Price(s) and volume(s)
No. of Shares
Price
2,017,000
8.65p
d.
Aggregated information
- Aggregated Volume
- Price
2,017,000
8.65p
e.
Date of the transaction
24 April 2026
f.
Place of the transaction
London Stock Exchange, AIM Market (XLON)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHDZLFLQZLFBBF